Tumor model selection also presents a limitation, as while the TRAMP-C1 and Myc-CaP models were chosen to represent distinct subtypes of advanced prostate cancer, the heterogeneity in PCa biology suggests the necessity for further validation in additional preclinical models, including patient-derived xenografts (PDXs) and genetically engineered mouse models (GEMMs), to ensure broader clinical applicability. This evidence concerns the gene MYC and posterior cortical atrophy.